RxCell, a Singapore-based biotech company focusing on cellular therapeutics for age-related diseases, raised $4.6M in funding.
The round saw participation from DMR Global Venture LLC and Regenosis.
The company intends to use the funds to secure the necessary resources, propelling its promising IND (Investigational New Drug) application testing and process.
Led by CEO Xianmin Zeng, RxCell is a advancing therapeutic applications of induced pluripotent stem cells (iPSCs). The firm intends to treat patients by replacing damaged or dysfunctional cells with healthy and functional iPSC-derived RPC (photoreceptors). They employ a combination of RPC and RPE with the primary aim of restoring vision.
Furthermore, RxCell is gearing up for a substantial second capital raise of $15M in Q4 2023. This upcoming fundraise is strategically designed to secure the necessary resources, propelling the company forward through its promising IND (Investigational New Drug) application testing and process.
FinSMEs
06/12/2023